You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
加科思-B(01167.HK):SHP2抑制劑兩項聯合用藥臨牀試驗完成首例患者給藥
格隆匯 06-18 08:09

格隆匯6月18日丨加科思-B(01167.HK)公佈,公司加科思在研的SHP2抑制劑JAB-3312與帕博利珠單抗(Pembrolizumab)及貝美替尼(Binimetinib)的聯合用藥臨牀試驗,已分別在美國完成首例兩名患者給藥,這是一項針對治療晚期實體瘤患者的1/2a期臨牀試驗。

根據雙方於2020年5月簽訂的許可及合作協議,這項臨牀進展將觸發公司與艾伯維(AbbVie)合作的里程碑付款條件,根據許可協議,公司將收到艾伯維2000萬美元的里程碑付款。

公司與艾伯維將共同在全球範圍內開發和商業化加科思自主研發的SHP2抑制劑,包括JAB-3068和JAB-3312。

根據許可協議中有關2020年9月已行使的在中國大陸、香港和澳門獨家開發和商業化SHP2抑制劑的選擇權,公司已授予AbbVie研究、開發、製造、商業化和以其他方式利用SHP2抑制劑的全球、獨家、可再許可的許可。由於中國選擇權已被行使,在有限的例外情況下,公司擁有開發、商業化和生產此類SHP2抑制劑產品的獨家權利(甚至對於艾伯維及其附屬公司),以尋求監管部門在相關地區內批准和商業化此類SHP2抑制劑。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account